Topics:
Pediatric Oncology • Medical Oncology • AYA • Hematology • Pediatric Hematology • Benign Hematology • Endocrinology
How do you monitor risk of erythrocytosis from testosterone use for female to male transgender patients?
Answer from: at Academic Institution
I utilize the Endocrine Society's guidelines for identifying secondary erythrocytosis secondary to gender affirming hormone therapy (GAHT) (PMID 28945902).
For initial monitoring, at baseline and then every 3 month hematocrit for the first year and 1-2 times yearly thereafter is typically implement...
Sign in or Register to read more